Leadership

Bill Lundberg, M.D. has served as a non-­executive director of our board of directors from June 2019 to December 2019, and as an executive director since December 2019. Since December 2019, Dr. Lundberg has served as our President and Chief Executive Officer. From January 2015 to February 2018, Dr. Lundberg was Chief Scientific Officer of CRISPR Therapeutics AG (CRISPR), a biotechnology company, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. From February 2011 to January 2015, Dr. Lundberg was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (Alexion), where he oversaw research and development from discovery through early-stage development, and prior to that, he was Director and Chief Medical Officer of Taligen Therapeutics, Inc. (Taligen), a biotechnology company, which was acquired by Alexion in 2011. Prior to Taligen, he held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Antisoma, Wyeth (now Pfizer), and Genzyme. Dr. Lundberg currently serves on the board of directors of the publicly traded life science company Vor Biopharma and Q32 Bio. Dr. Lundberg received an M.D. from Stanford University and M.B.A. from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/M.I.T., and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute.

Peter B. Silverman, J.D. has served as the Company’s Chief Operating Officer since January 2023, and our General Counsel since February 2018 and Chief Intellectual Property Officer since February 2017, with prior roles including Head of Utrecht from April 2020 to January 2023.

He is responsible for the Company’s operations, including clinical operations, business strategy, legal and intellectual property, and information technology departments. Prior to joining Merus, Mr. Silverman was a Partner at Kirkland & Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters and technologies. Mr. Silverman was an associate at Kaye Scholer LLP (now Arnold & Porter Kaye Scholer LLP), and prior to that Mr. Silverman also served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey. He holds a J.D. from Fordham University School of Law, graduating magna cum laude and Order of the Coif. He is admitted to practice law in New York. Mr. Silverman also holds a B.A. in biology from the University of Rochester.

Cornelis Adriaan (“John”) de Kruif, Ph.D. has served as our Chief Technology Officer since January 2013 and previously served as our Chief Scientific Officer from April 2007 to January 2013.

His responsibilities include management of antibody discovery, antibody platform technology development, antibody engineering, external collaborations, partnerships management and operational activities. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company, specializing in vaccines and biopharmaceutical technology. Dr. de Kruif holds a Ph.D., in Antibody Engineering from Utrecht University.

Cecilia (“Cecile”) Anna Wilhelmina Geuijen, Ph.D has served as our Chief Scientific Officer since May 2021.

Her responsibilities include strategic scientific leadership, management of pre-clinical research, external collaborations, partnerships management and operational activities. Before joining Merus in 2009, Dr. Geuijen worked as a senior scientist on the evaluation of new therapeutic targets in oncology at Genmab and the identification of new therapeutic targets in oncology at Crucell. She holds a Ph.D. in Biology from the University of Utrecht and was a Marie Curie Fellow at the Duve Institute in Brussels.

Shannon Campbell has served as our Chief Commercial Officer since February 2022.

She is responsible for the global commercialization strategy and activity at Merus. Ms. Campbell has over 25 years of pharmaceutical commercialization experience across a wide range of geographies, markets and product lifecycles. She’s successfully led 25+ specialty brands, including 11 new chemical entity launches across key markets and regions globally. Ms. Campbell most recently led the U.S. Solid Tumor Franchise at Novartis  Pharmaceuticals Corporation where she was responsible for a broad portfolio of oncology and rare disease products. During her time there, she led diverse teams and drove strong commercial execution including multiple launches that changed the standard of care in breast and targeted lung cancers. Prior to Novartis, Ms. Campbell helped to build, launch and subsequently lead Bayer HealthCare Pharmaceuticals US Oncology Business Unit. Prior to Bayer, she held positions of increasing responsibility at Abbott Labs and the Pharmacia heritage companies (Pharmacia & Upjohn, The Upjohn Company). ). She currently serves on the board of directors of Black Diamond Therapeutics. Ms. Campbell holds a Bachelor of Science degree from Ithaca College, and completed several advanced leadership, strategy and finance programs at the University of Michigan Ross School of Business, IMD, Harvard Business School and Wharton.

Ashley Pereira, Pharm.D. has served as our Senior Vice President of Regulatory Affairs since September 2021.

His responsibilities include overseeing the regulatory strategies and activities that advance the development of our clinical programs and maintaining effective and collaborative working relationships with regulatory authorities worldwide. He brings nearly 20 years of clinical-regulatory drug development experience. Dr. Pereira was most recently the Global Regulatory Sciences Deputy Head for hematology therapeutic at Bristol-Myers Squibb (BMS) where he provided direct oversight to the multiple myeloma and lymphoma regulatory teams. Previously, he held numerous roles with increasing responsibilities at BMS, including supporting the development of OPDIVO® (Nivolumab) as the Global Regulatory Group Leader for the Head & Neck, Gastric, Hepatocellular Carcinoma development teams. Dr. Pereira was also the regulatory head for new oncology assets including major collaborations/partnered assets in late stage development. Dr. Pereira holds a Doctorate of Pharmacy from Philadelphia College of Pharmacy & Science.

Ernesto Wasserman, M.D. has served our company since December 2016, first as our Vice President of Clinical Development and currently as Senior Vice President of Clinical Development since January 2022.

His responsibilities include overseeing the planning and executing of clinical programs from early stage through to potential registration. He has over 20 years of experience in oncology clinical drug development. Prior to joining Merus, Dr. Wasserman held positions of increasing responsibility at Novartis, leading development of early and late stage small molecules and biologics in oncology. Notably, he played a key role in the execution of a pivotal clinical program in metastatic melanoma leading to regulatory approval of Braftovi and Mektovi, and contributing to the clinical strategy for Novartis™ immuno-oncology portfolio. Dr. Wasserman is a board certified oncologist; he received his M.D. from the University of Buenos Aires, completed a fellowship in medical oncology at Hopital Paul Brousse (Paris) and visiting fellowships at Hospital 12 de Octubre (Madrid), Memorial Sloan Kettering (New York), and the National Cancer Center (Japan).

Audrey Bergan has served as our Chief People Officer since November 2024. She is responsible for overseeing the Global human resource (HR) strategy and management at Merus. Ms. Bergan has over 25 years of attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. Prior to joining Merus, she was the Senior Vice President, Chief Human Resources Officer, at ImmunoGen from 2014 through its acquisition by AbbVie in May 2024. At ImmunoGen, Ms. Bergan was responsible for Global HR strategy, including talent acquisition and management, leadership and organizational development, benefits, compensation and HR systems. Ms. Bergan joined ImmunoGen from Philips where she was the Director of Talent Acquisition, Executive Services Americas. Previously, she spent eight years at Biogen in multiple talent acquisition leadership roles. Earlier in her career, Ms. Bergan worked for BMS, Cubist, Therion Biologics and Wyeth/Genetics Institute in talent acquisition. Ms. Bergan received a Master of Science in Human Resource Counseling from Northeastern University and a Bachelor of Arts in Psychology from University of Massachusetts Amherst.

Greg D. Perry served as a non-executive director of our board of directors since May 2016 and Vice Chairperson of our board of directors since August 2018. Since June 2023, Mr. Perry has served as our Chief Financial Officer (CFO).

His responsibilities include serving as the Principal Financial Officer, and overseeing the finance and quality functions of our organization. From May 2018 until his retirement in April 2022, Mr. Perry served as the CFO at Finch Therapeutics Group. Mr. Perry served as the Chief Financial and Administrative Officer of Novelion Therapeutics Inc. from November 2016 to December 2017. Prior to Novelion, Mr. Perry was CFO of Aegerion Pharmaceuticals Inc. from July 2015 until its merger with Novelion in November 2016. He has also served as CFO of several additional biotechnology companies, and earlier in his career he held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Mr. Perry currently serves on the board of directors of Kala Pharmaceuticals. Mr. Perry received a B.A. in Economics and Political Science from Amherst College.

Fabian Zohren, M.D., Ph.D. has served as our Chief Medical Officer since July 2024. His responsibilities include leading clinical development at Merus. Dr. Zohren is a proven late-stage clinical development expert and most recently he was Chief Medical Officer at ImmunoGen from November 2023 through its acquisition by AbbVie in May 2024. Prior to ImmunoGen, Dr. Zohren worked at Pfizer from 2017 until 2023 where he most recently served as Global Clinical Development Leader for prostate cancer and DNA repair, a role which included Xtandi® (enzalutamide) and Talzenna® (talazoparib) with oversight of two clinical programs encompassing >8000 treated patients and 8 global phase 3 registrational studies in prostate and breast cancer. Earlier in his career at Pfizer, he was the Senior Medical Director and Global Clinical Leader for prostate cancer and gynecological malignancies. He joined Pfizer from Millennium Pharmaceuticals/Takeda where he was the Senior Medical Director and Early Clinical Development Leader for their Cell Signaling Franchise since 2012. Dr. Zohren received his Medical Degree and Ph.D. from the University of Dusseldorf and was a research scholar at Baylor College of Medicine in the Center for Cell and Gene Therapy.

Anand Mehra, M.D. has served as a non-executive director since August 2015 and as Chairperson of our board of directors effective since June 2020. Dr. Mehra held various positions at Sofinnova Investments (f.k.a. Sofinnova Ventures) from 2007 to January 2020, most recently holding the position of a managing general partner, where he focused on working with entrepreneurs to build drug development companies. He led the firm’s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. (“Aclaris”), and Spark Therapeutics. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan’s private equity and venture capital group and as a consultant at McKinsey & Company. He currently serves as a member of the board of directors of the publicly held life science company Aclaris. Within the past five years, he also served on the boards of directors of the publicly held life science companies Marinus Pharmaceuticals, Inc., Spark Therapeutics, Inc. and Aerie Pharmaceuticals. Dr. Mehra received a B.A. degree in political philosophy from the University of Virginia and an M.D. degree from Columbia University’s College of Physicians and Surgeons.

Mark Iwicki has served as a non-executive director of our board of directors since June 2015. From June 2015 until July 2018, Mr. Iwicki served as the Chairperson of our board of directors. Mr. Iwicki currently serves as the Chairperson and Chief Executive Officer of Kala Pharmaceuticals, Inc., a pharmaceutical company, where he has been employed since April 2015. From February 2014 to November 2014 Mr. Iwicki served as President and Chief Executive Officer of Civitas Therapeutics. From December 2012 to January 2014, Mr. Iwicki served as President and Chief Executive Officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr. Iwicki served in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc., a pharmaceutical company. From 1998 to 2007, Mr. Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals Corporation, a pharmaceutical company. Mr. Iwicki currently serves on the boards of directors of publicly held life science companies Akero Therapeutics, Inc., Kala Pharmaceuticals, Inc and Q32 Bio. Within the past five years, he also served on the board of directors of the publicly held life science company Aimmune Therapeutics Inc. and Pulmatrix, Inc. Mr. Iwicki received a B.A. in business administration from Ball State University and an M.B.A. from Loyola University.

Len Kanavy has served as a non-executive director of our board of directors since July 2018. Mr. Kanavy most recently served as Senior Vice President, Commercial Business Operations at Genentech, a biotechnology company, from September 2006 to September 2016, where he was responsible for strategic decisions for the U.S. commercial business, including product launches, valuation of business development opportunities, clinical development plan options and pricing. From 2014 to 2016, he was a board member of the Genentech Access to Care Foundation. Prior to joining Genentech, Mr. Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business analytics, strategy, and product launches. Mr. Kanavy holds a B.S. in Business Administration and an M.B.A. with a specialization in Finance from the University of Scranton.

Bill Lundberg, M.D. has served as a non-­executive director of our board of directors from June 2019 to December 2019, and as an executive director since December 2019. Since December 2019, Dr. Lundberg has served as our President and Chief Executive Officer. From January 2015 to February 2018, Dr. Lundberg was Chief Scientific Officer of CRISPR Therapeutics AG (CRISPR), a biotechnology company, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. From February 2011 to January 2015, Dr. Lundberg was Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, Inc. (Alexion), where he oversaw research and development from discovery through early-stage development, and prior to that, he was Director and Chief Medical Officer of Taligen Therapeutics, Inc. (Taligen), a biotechnology company, which was acquired by Alexion in 2011. Prior to Taligen, he held roles of increasing responsibility in clinical drug development and medical affairs at Xanthus/Antisoma, Wyeth (now Pfizer), and Genzyme. Dr. Lundberg currently serves on the board of directors of the publicly traded life science company Vor Biopharma and Q32 Bio. Dr. Lundberg received an M.D. from Stanford University and M.B.A. from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/M.I.T., and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute.

Paolo Pucci has served as a non-executive director of our board of directors since June 2020. Mr. Pucci served as the Chief Executive Officer of ArQule, Inc. (ArQule), a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics, from June 2008 until its acquisition by Merck Inc. in January 2020. Prior to joining ArQule, Mr. Pucci worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities including President of the Oncology & Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Mr. Pucci held positions of increasing responsibility with Eli Lilly and Company from July 1991 to April 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Mr. Pucci earned an M.S. in economics and accounting from Università degli Study di Napoli Federico II and an M.B.A. in marketing and finance from the University of Chicago. Within the past five years, Mr. Pucci previously served on the boards of directors of Algeta ASA, until its acquisition by Bayer AG, and Dyax Inc., until its acquisition by Shire Plc (which was subsequently acquired by Takeda Pharmaceutical Company Ltd.), New Link Genetics Inc, ArQule Inc., until its acquisition by Merck Inc., and Trillium Therapeutics Inc., until its acquisition by Pfizer Inc. He currently serves on the boards of directors of publicly held life sciences companies West Pharmaceuticals Services, Inc., and Replimmune Group Inc.

Victor Sandor, M.D.C.M. has served as a non-executive director of our board of directors since June 2019. From September 2014 to December 2019, Dr. Sandor was the Chief Medical Officer at Array BioPharma (Array), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Braftovi® and Mektovi® for the treatment of BRAFV600E/K mutant melanoma and Braftovi for the treatment of BRAFV600E mutant colorectal cancer. Prior to joining Array, from February 2010 to September 2014, he was Senior Vice President for Global Clinical Development at Incyte Corporation (Incyte), a pharmaceutical company, where he oversaw clinical development through regulatory approval of Jakafi® for the treatment of myelofibrosis and polycythemia vera. Prior to joining Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec and, prior to that held positions of increasing responsibility in oncology product development at AstraZeneca, where he played a lead role in the registration of Arimidex® (anastrozole) for adjuvant use and the development of early stage programs through proof-of-concept. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. He currently serves on the boards of directors of publicly held life sciences companies ADC Therapeutics, Prelude Therapeutics and Kymera Therapeutics.

Maxine Gowen, Ph.D., has served as a non-­executive director to our board of directors since May 2021. Dr. Gowen was the founding President and Chief Executive Officer of Trevena, Inc. (Trevena), from 2007 to October 2018. Prior to this position, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of 15 years. As Senior Vice President for the company’s Center of Excellence for Drug Discovery, she developed an innovative new approach to externalizing drug discovery. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the boards of directors of numerous companies. Dr. Gowen also previously served as Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, where she was responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen currently serves on the boards of directors of publicly held life science companies Aclaris and Passage Bio, and served on the boards of directors of publicly held life science companies Akebia Therapeutics (Akebia) and Trevena until May 2021 and Aceragen, Inc., until August 2023. Dr. Gowen holds a B.Sc. in biochemistry from the University of Bristol, U.K., received a Ph.D. in cell biology from the University of Sheffield, U.K., and received an M.B.A. from the Wharton School of the University of Pennsylvania.

Jason Haddock has served as a non-executive member of our board of directors since May 2024. Most recently, he served as Chief Financial Officer (CFO) at Archer Dx from May to August 2020 until it was acquired by Invitae Corporation. From 2016 to 2019, he served as CFO of Array BioPharma, Inc. and from 2015 to 2016, Mr. Haddock served as CFO and Chief Operating Officer (COO) of BERG. Mr. Haddock spent 15 years (2001-2015) at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. He currently serves on the board of directors of PYC Therapeutics. Mr. Haddock holds a BS in accounting from Illinois State University and an Executive MBA from Washington University in St. Louis.

Dr. Ribas is a Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). He also currently serves as Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC), Chair of the Melanoma Committee of the South West Oncology Group (SWOG) and a member of the Board of Directors of the American Association for Cancer Research (AACR).

Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA. He trained at the University of Barcelona with postdoctoral research and clinical fellowships completed at UCLA.

Dr. Schumacher is a Senior Member at The Netherlands Cancer Institute, Professor of Immunotechnology at Leiden University Medical Center, Venture Partner at Third Rock Ventures and a scientific advisor to several emerging biotechnology companies. Dr. Schumacher is also the Founder of Neon Therapeutics and AIMM Therapeutics. He previously served as Chief Scientific Officer of Kite Pharma EU, which was formed following Kite Pharma’s acquisition of T Cell Factory, a company

Dr. Schumacher founded. Dr. Schumacher received his Ph.D. from The Netherlands Cancer Institute, a M.Sc. in medical biology from the University of Amsterdam and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.

Dr. Tabernero is the Director of the Vall d’Hebron Institute of Oncology (VHIO), Associate Professor in the Medicine Department at the Universitat Autònoma de Barcelona, and Director of Innovation, Care and Research at the Catalonian Oncology Network. Dr. Tabernero also holds several roles in the Medical Oncology Department at the Vall d’Hebron University Hospital, including Head of the Department, Clinical Director and Head of the Gastrointestinal Tumors Services and Phase 1 Unit.

Dr. Tabernero is a physician-scientist who conducts laboratory and clinical research in the field of gastrointestinal tumors with particular focus in early drug development. Dr. Tabernero received his M.D. and Ph.D. from the Universitat Autònoma de Barcelona.